Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38191799)

  • 1. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
    Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
    Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity.
    Yang M; Zhang Z; Chen J; Xu M; Huang J; Wang M; Li W; Wan X; Yuen MF; Luo X; Xi D; Ning Q
    J Exp Clin Cancer Res; 2019 Aug; 38(1):351. PubMed ID: 31409352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13.
    Luft O; Khattar R; Farrokhi K; Ferri D; Yavorska N; Zhang J; Sadozai H; Adeyi O; Chruscinski A; Levy GA; Selzner N
    Immunology; 2018 Jul; 154(3):476-489. PubMed ID: 29341118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer.
    Zhu Y; Zhang L; Zha H; Yang F; Hu C; Chen L; Guo B; Zhu B
    Int J Biol Sci; 2017; 13(6):804-814. PubMed ID: 28656005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE.
    Khattar R; Luft O; Yavorska N; Shalev I; Phillips MJ; Adeyi O; Gao D; Bartczak A; Urbanellis P; Shyu W; Zhang J; Manuel J; Levy GA; Selzner N
    PLoS One; 2013; 8(10):e72309. PubMed ID: 24146739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression.
    Liu H; Shalev I; Manuel J; He W; Leung E; Crookshank J; Liu MF; Diao J; Cattral M; Clark DA; Isenman DE; Gorczynski RM; Grant DR; Zhang L; Phillips MJ; Cybulsky MI; Levy GA
    Eur J Immunol; 2008 Nov; 38(11):3114-26. PubMed ID: 18991288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice.
    Wang J; Vuitton DA; Müller N; Hemphill A; Spiliotis M; Blagosklonov O; Grandgirard D; Leib SL; Shalev I; Levy G; Lu X; Lin R; Wen H; Gottstein B
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003755. PubMed ID: 25955764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells.
    Wu L; Liu X; Lei J; Zhang N; Zhao H; Zhang J; Deng H; Li Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity.
    Chruscinski A; Sadozai H; Rojas-Luengas V; Bartczak A; Khattar R; Selzner N; Levy GA
    Rambam Maimonides Med J; 2015 Jul; 6(3):. PubMed ID: 26241231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.
    Yuan X; Li Y; Zhang AZ; Jiang CH; Li FP; Xie YF; Li JF; Liang WH; Zhang HJ; Liu CX; Pang LJ; Shen XH; Li F; Hu JM
    Aging (Albany NY); 2020 Dec; 13(2):2049-2072. PubMed ID: 33323552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.
    Shalev I; Wong KM; Foerster K; Zhu Y; Chan C; Maknojia A; Zhang J; Ma XZ; Yang XC; Gao JF; Liu H; Selzner N; Clark DA; Adeyi O; Phillips MJ; Gorczynski RR; Grant D; McGilvray I; Levy G
    Hepatology; 2009 Feb; 49(2):387-97. PubMed ID: 19085958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.
    Zhang S; Rao G; Heimberger A; Li S
    Cytokine Growth Factor Rev; 2023 Feb; 69():73-79. PubMed ID: 36085259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Fgl2 restricts autoimmune hepatitis progression via suppressing Tc17 and conventional CD8+ T cell function.
    Ai G; Yan W; Yu H; Xiao F; Xi D; Ma K; Huang J; Luo X; Wan X; Ning Q
    J Gene Med; 2018 Jul; 20(7-8):e3023. PubMed ID: 29756667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts.
    Urbanellis P; Shyu W; Khattar R; Wang J; Zakharova A; He W; Sadozai H; Amir AZ; Shalev I; Phillips MJ; Adeyi O; Ross H; Grant D; Levy GA; Chruscinski A
    Immunology; 2015 Jan; 144(1):91-106. PubMed ID: 24990517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological functions and clinical implications of fibrinogen-like 2: A review.
    Yang G; Hooper WC
    World J Clin Infect Dis; 2013 Aug; 3(3):37-46. PubMed ID: 26161303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.
    Shalev I; Liu H; Koscik C; Bartczak A; Javadi M; Wong KM; Maknojia A; He W; Liu MF; Diao J; Winter E; Manuel J; McCarthy D; Cattral M; Gommerman J; Clark DA; Phillips MJ; Gorczynski RR; Zhang L; Downey G; Grant D; Cybulsky MI; Levy G
    J Immunol; 2008 Jan; 180(1):249-60. PubMed ID: 18097026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.
    Bartczak A; Chruscinski A; Mendicino M; Liu H; Zhang J; He W; Amir AZ; Nguyen A; Khattar R; Sadozai H; Lobe CG; Adeyi O; Phillips MJ; Zhang L; Gorczynski RM; Grant D; Levy GA
    Am J Transplant; 2016 Jun; 16(6):1739-50. PubMed ID: 26718313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.